142 related articles for article (PubMed ID: 38039101)
1. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
[TBL] [Abstract][Full Text] [Related]
2. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.
Halvorson SA; Gilbert E; Hopkins RS; Liu H; Lopez C; Chu M; Martin M; Sheppard B
J Gen Intern Med; 2013 Nov; 28(11):1525-9. PubMed ID: 23681843
[TBL] [Abstract][Full Text] [Related]
3. Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor.
Wu SL; Bai JG; Xu J; Ma QY; Wu Z
World J Surg Oncol; 2014 Jul; 12():220. PubMed ID: 25029913
[TBL] [Abstract][Full Text] [Related]
4. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour.
Eldor R; Glaser B; Fraenkel M; Doviner V; Salmon A; Gross DJ
Clin Endocrinol (Oxf); 2011 May; 74(5):593-8. PubMed ID: 21470282
[TBL] [Abstract][Full Text] [Related]
5. Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.
Saavedra C; Lamarca A; Hubner RA
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31401568
[TBL] [Abstract][Full Text] [Related]
6. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.
Li W; Yang X; Deng Y; Jiang Y; Xu G; Li E; Wu Y; Ren J; Ma Z; Dong S; Han L; Ma Q; Wu Z; Wang Z
Sci Rep; 2022 May; 12(1):9053. PubMed ID: 35641533
[TBL] [Abstract][Full Text] [Related]
7. Necrolytic migratory erythema and glucagonoma rising from pancreatic head.
Tseng HC; Liu CT; Ho JC; Lin SH
Pancreatology; 2013; 13(4):455-7. PubMed ID: 23890147
[TBL] [Abstract][Full Text] [Related]
8. Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.
Tremblay C; Marcil I
J Cutan Med Surg; 2017; 21(6):559-561. PubMed ID: 28662584
[TBL] [Abstract][Full Text] [Related]
9. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.
Kindmark H; Sundin A; Granberg D; Dunder K; Skogseid B; Janson ET; Welin S; Oberg K; Eriksson B
Med Oncol; 2007; 24(3):330-7. PubMed ID: 17873310
[TBL] [Abstract][Full Text] [Related]
10. Glucagonoma syndrome with severe erythematous rash: A rare case report.
Wang ZX; Wang F; Zhao JG
Medicine (Baltimore); 2019 Sep; 98(37):e17158. PubMed ID: 31517863
[TBL] [Abstract][Full Text] [Related]
11. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
Tolliver S; Graham J; Kaffenberger BH
Int J Dermatol; 2018 Jun; 57(6):642-645. PubMed ID: 29450880
[TBL] [Abstract][Full Text] [Related]
12. The glucagonoma syndrome. Clinical and pathologic features in 21 patients.
Wermers RA; Fatourechi V; Wynne AG; Kvols LK; Lloyd RV
Medicine (Baltimore); 1996 Mar; 75(2):53-63. PubMed ID: 8606627
[TBL] [Abstract][Full Text] [Related]
13. Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome.
Otto AI; Marschalko M; Zalatnai A; Toth M; Kovacs J; Harsing J; Tulassay Z; Karpati S
J Am Acad Dermatol; 2011 Aug; 65(2):458-459. PubMed ID: 21763589
[No Abstract] [Full Text] [Related]
14. Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.
Kimbara S; Fujiwara Y; Toyoda M; Chayahara N; Imamura Y; Kiyota N; Mukohara T; Fukunaga A; Oka M; Nishigori C; Minami H
Clin J Gastroenterol; 2014 Jun; 7(3):255-9. PubMed ID: 26183746
[TBL] [Abstract][Full Text] [Related]
15. Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema.
Chen HW; Chen HW; Su DH; Shun CT; Liu KL
J Formos Med Assoc; 2005 May; 104(5):363-6. PubMed ID: 15959605
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic glucagonoma with pancreatic calcification.
Gupta RA; Udwadia FE; Agrawal P; Doctor N
Pancreatology; 2013; 13(3):327-9. PubMed ID: 23719610
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide.
Oberkirchner U; Linder KE; Zadrozny L; Olivry T
Vet Dermatol; 2010 Oct; 21(5):510-6. PubMed ID: 20500495
[TBL] [Abstract][Full Text] [Related]
18. Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine.
Jiménez-Gallo D; Ossorio-García L; de la Varga-Martínez R; Arjona-Aguilera C; Linares-Barrios M
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28508546
[No Abstract] [Full Text] [Related]
19. Glucagonoma Syndrome: A Rare Paraneoplastic Disorder due to Neuroendocrine Tumor of the Pancreas.
Yusuf MA; Mehmood S; Iftikhar J; Saqib M; Siddique MZ; Imtiaz W
J Coll Physicians Surg Pak; 2022 Aug; 32(8):S147-S149. PubMed ID: 36210677
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Glucagonoma-Related Necrolytic Migratory Erythema With Peptide Receptor Radionuclide Therapy.
Mavi ME; Tuncel M
Clin Nucl Med; 2021 Dec; 46(12):1002-1003. PubMed ID: 34034327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
